WO2006123678A1 - ドロキシドパを含有する安定な錠剤 - Google Patents
ドロキシドパを含有する安定な錠剤 Download PDFInfo
- Publication number
- WO2006123678A1 WO2006123678A1 PCT/JP2006/309801 JP2006309801W WO2006123678A1 WO 2006123678 A1 WO2006123678 A1 WO 2006123678A1 JP 2006309801 W JP2006309801 W JP 2006309801W WO 2006123678 A1 WO2006123678 A1 WO 2006123678A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tablet
- starch
- corn
- tablet according
- droxidopa
- Prior art date
Links
- 229960001104 droxidopa Drugs 0.000 title claims abstract description 63
- QXWYKJLNLSIPIN-SFYZADRCSA-N droxidopa Chemical compound OC(=O)[C@H](N)[C@@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-SFYZADRCSA-N 0.000 title claims abstract 10
- 229920002472 Starch Polymers 0.000 claims abstract description 62
- 239000008107 starch Substances 0.000 claims abstract description 62
- 235000019698 starch Nutrition 0.000 claims abstract description 62
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 47
- 239000011230 binding agent Substances 0.000 claims abstract description 47
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 45
- 235000005822 corn Nutrition 0.000 claims abstract description 45
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 28
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 17
- 235000010355 mannitol Nutrition 0.000 claims abstract description 16
- 239000004386 Erythritol Substances 0.000 claims abstract description 15
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims abstract description 15
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 15
- 229930195725 Mannitol Natural products 0.000 claims abstract description 15
- 235000019414 erythritol Nutrition 0.000 claims abstract description 15
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims abstract description 15
- 229940009714 erythritol Drugs 0.000 claims abstract description 15
- 239000008101 lactose Substances 0.000 claims abstract description 15
- 239000000594 mannitol Substances 0.000 claims abstract description 15
- 229920000881 Modified starch Polymers 0.000 claims abstract description 14
- 239000004368 Modified starch Substances 0.000 claims abstract description 13
- 229930006000 Sucrose Natural products 0.000 claims abstract description 13
- 235000019426 modified starch Nutrition 0.000 claims abstract description 13
- 239000005720 sucrose Substances 0.000 claims abstract description 13
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 12
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 12
- 229920002678 cellulose Polymers 0.000 claims abstract description 10
- 239000001913 cellulose Substances 0.000 claims abstract description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 8
- 239000008103 glucose Substances 0.000 claims abstract description 8
- 229920002261 Corn starch Polymers 0.000 claims description 46
- 239000008120 corn starch Substances 0.000 claims description 46
- 240000008042 Zea mays Species 0.000 claims description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 29
- 238000004519 manufacturing process Methods 0.000 claims description 22
- 210000000214 mouth Anatomy 0.000 claims description 21
- 239000002245 particle Substances 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 238000005469 granulation Methods 0.000 claims description 15
- 230000003179 granulation Effects 0.000 claims description 15
- 239000000654 additive Substances 0.000 claims description 9
- 239000007884 disintegrant Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 4
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 claims description 2
- 230000005484 gravity Effects 0.000 claims description 2
- 235000009973 maize Nutrition 0.000 claims description 2
- 238000007907 direct compression Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 11
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract description 8
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract description 7
- 241000209149 Zea Species 0.000 abstract 2
- 239000003826 tablet Substances 0.000 description 132
- QXWYKJLNLSIPIN-JGVFFNPUSA-N droxidopa Chemical compound OC(=O)[C@@H](N)[C@H](O)C1=CC=C(O)C(O)=C1 QXWYKJLNLSIPIN-JGVFFNPUSA-N 0.000 description 60
- 229940099112 cornstarch Drugs 0.000 description 42
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 18
- 238000009472 formulation Methods 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 235000019359 magnesium stearate Nutrition 0.000 description 9
- 238000003860 storage Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 235000010980 cellulose Nutrition 0.000 description 8
- 238000011156 evaluation Methods 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 239000000314 lubricant Substances 0.000 description 8
- 239000004570 mortar (masonry) Substances 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 229940127557 pharmaceutical product Drugs 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 5
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000004040 coloring Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 239000000811 xylitol Substances 0.000 description 4
- 235000010447 xylitol Nutrition 0.000 description 4
- 229960002675 xylitol Drugs 0.000 description 4
- 239000004605 External Lubricant Substances 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- -1 dalcose Chemical compound 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940088679 drug related substance Drugs 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000005461 lubrication Methods 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- STFSJTPVIIDAQX-LTRPLHCISA-M sodium;(e)-4-octadecoxy-4-oxobut-2-enoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOC(=O)\C=C\C([O-])=O STFSJTPVIIDAQX-LTRPLHCISA-M 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000002274 desiccant Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical compound OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 229920003114 HPC-L Polymers 0.000 description 1
- 206010027146 Melanoderma Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000001089 Multiple system atrophy Diseases 0.000 description 1
- 206010031127 Orthostatic hypotension Diseases 0.000 description 1
- 240000002825 Solanum vestissimum Species 0.000 description 1
- 235000018259 Solanum vestissimum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 239000003230 hygroscopic agent Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002597 lactoses Chemical class 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- DVQHRBFGRZHMSR-UHFFFAOYSA-N sodium methyl 2,2-dimethyl-4,6-dioxo-5-(N-prop-2-enoxy-C-propylcarbonimidoyl)cyclohexane-1-carboxylate Chemical compound [Na+].C=CCON=C(CCC)[C-]1C(=O)CC(C)(C)C(C(=O)OC)C1=O DVQHRBFGRZHMSR-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Definitions
- the present invention relates to a droxidopa tablet excellent in storage stability and ease of taking.
- Droxidopa is a drug mainly used to improve freezing and dizziness in Parkinson's disease patients and to treat orthostatic hypotension in patients with analysis. Droxidopa was difficult to tablet because it colored when combined with various excipients or additives such as binders and under humidification. Therefore, at present, only droxidopa preparations are commercially available as dry capsules and fine granules granulated with an organic solvent without using water, and capsules are prescribed for most patients.
- the dosage form that is most likely to be taken is tablets, and capsules are uncomfortable due to adhesion to the throat, etc.
- Tablets that are better to take than capsules especially because patients with Parkinson's disease, who take droxidopa, have many elderly people, and the proportion of patients whose swallowing ability has decreased due to the progression of the disease. It was desired to develop a tablet that rapidly disintegrates in the oral cavity and does not cause discomfort and is easy to take and rapidly disintegrates in the oral cavity.
- Patent Document 1 discloses a rapidly disintegrating tablet containing polybutyl alcohol, and droxidopa is mentioned as a medicinal component that can be used.
- Patent Document 2 discloses a tablet that rapidly disintegrates in the oral cavity, characterized by containing starch as a water-soluble excipient (binder), and mentions droxidopa as a medicinal ingredient. Yes.
- Patent Document 1 International Publication Pamphlet No. 01/064190
- Patent Document 2 International Publication Pamphlet No. 00/47233
- Patent Document 1 Hospital Pharmacy Vol.ll, No.3, 284-292 (1985)
- the problem to be solved by the present invention is to provide a droxidopa tablet excellent in storage stability and ease of taking.
- a tablet containing droxidopa as an active ingredient which contains at least one excipient selected from mannitol, lactose, erythritol, glucose, sucrose, crystalline cellulose and corn-derived starch.
- Binding power A tablet according to [4] or [5], which is a modified starch derived from corn;
- At least one excipient selected from mannitol, erythritol and lactose,
- Excipient The tablet according to any one of [14] to [17], wherein the specific gravity by weight of the total amount of starch derived from corn is 5: 5 to 9.5: 0.5;
- the granulated production intermediate is dried and has a moisture content of 1% by weight or less. Preparing a granular production intermediate;
- the present invention it has become possible to produce a droxidopa tablet that does not cause coloring and can maintain quality for a long period of time.
- the droxidopa tablet of the present invention does not require any special production equipment, can be easily produced with ordinary equipment, and has an appropriate hardness that does not collapse during the distribution process.
- the tablet of the present invention is of an appropriate size that is easy to handle and immediately take.
- the tablet of the present invention can be an intraoral rapidly disintegrating tablet that rapidly disintegrates in the oral cavity, and can improve the compliance for elderly people with reduced swallowing ability.
- the mannitol, lactose, erythritol, glucose, sucrose (purified sucrose) and crystalline cellulose used in the present invention are not particularly limited, and are generally used by those skilled in the art as "Japanese Pharmacopoeia” or " Those described in “Pharmaceutical Additive Specifications” can be used.
- Japanese Pharmacopoeia Japanese Pharmacopoeia
- Those described in “Pharmaceutical Additive Specifications” can be used.
- the average particle size of these excipients is not particularly limited, but is preferably 10 to 500 m, more preferably 20 to 200 ⁇ m, and more preferably 20 to LOO ⁇ m.
- a method for measuring the particle size for example, a method using a laser diffraction / scattering particle size distribution measuring device to measure a particle size on the order of micrometers, or a method of measuring a particle size on the order of nanometers.
- a method using a dynamic light scattering type particle size distribution measuring apparatus can be mentioned.
- a pulverized product is appropriately used as necessary.
- the pulverization method include an air pulverizer and a hammer type pulverizer.
- Polybulal alcohol is, for example, a polymerization obtained by saponifying polyacetic acid bull. As long as it is acceptable for use as a pharmaceutical product, there is no particular limitation, and those having a saponification degree of 78 to 96 mol% can be used.
- the polybulal alcohol has a viscosity at 20 ° C of a 4 wt% aqueous solution measured with a Heppler viscometer, 1 to 50 mPa's, more preferably 2 to 40 mPa's, still more preferably 3 to 30 mPa's, and more. It is preferably 4 to 20 mPa's, particularly preferably 4.5 to 6 mPa's.
- corn starch includes any natural corn starch without particular limitation as long as it is usually used as a pharmaceutical product. Uchi seeds are preferably used, and white corn as a raw material is particularly preferable.
- the average particle size is not particularly limited, but preferably 100 ⁇ m or less, more preferably 50 ⁇ m or less.
- corn-derived starch refers to not only “corn starch” but also “corn-derived modified starch” obtained by subjecting the corn starch to a heat treatment or a chemical treatment. It is a concept that also includes “ The modified starch derived from corn is not particularly limited as long as it can be used as a pharmaceutical product, for example, derived from corn starch such as soluble starch, alpha-unified starch, partially-alpha-denified starch, and hydroxypropylated starch. Of the modified starch.
- modified starch derived from corn starch, that is, a modified starch obtained by heat treatment, is preferably used after chemical modification such as introduction of a substituent by a chemical reaction.
- specific examples include alpha-ized starch and partially alpha-ized starch.
- a commercial item can also be used as said alpha-ized starch or partial alpha-ized starch. It is also possible to use a viscous liquid dampening obtained by dispersing corn starch in water and subjecting it to heat treatment to partially or entirely alpha-ize it.
- these alpha-ized starch or partially-alpha-ized starch will be referred to as “a part or all of the alpha-ized corn. It is called “starch”.
- the viscous liquid starch is suitable for use as a binding liquid when granulating.
- Corn starch that is partially or fully alpha-ized in a viscous liquid state can be produced by the following method. That is, by dispersing corn starch in water at a ratio of 0.5 to 10% and heat-treating at 60 ° C to 100 ° C for 0.1 to 15 minutes, corn starch partially or entirely corn starch is alpha-ized. Can be obtained. Preferably, it is 62 to 95 ° C, more preferably 65 ° C to 85 ° C, particularly preferably 68 to 75 ° C, preferably 0.5 to 10 minutes, more preferably 1 to 8 minutes, particularly preferably 2 to Use partially or fully alpha-denatured corn starch as a binder.
- the excipient used in the present invention is acceptable for use as a pharmaceutical product, and does not affect the stability of droxidopa depending on the formulation. Specifically, it represents at least one selected from mannitol, lactose, erythritol, glucose, sucrose, crystalline cellulose and corn-derived starch power and a mixture thereof. That is, by using these excipients, tablets containing droxidopa that can withstand long-term storage without being colored can be produced.
- disintegrating surface strength particularly mantol, erythritol or Among the preferred lactoses, mannitol is particularly preferred.
- "rapidly disintegrates in the oral cavity” is preferably within 80 seconds, more preferably within 60 seconds, and more preferably within 60 seconds after the addition of a power tablet slightly different depending on the person. Preferably collapse completely within 40 seconds, particularly preferably within 30 seconds! Uh.
- the binder used in the present invention is acceptable for use as a pharmaceutical product and is at least one binder selected from corn-derived starch and polyvinyl alcohol. That is, by using these binders, tablets containing droxidopa that can withstand long-term storage without being colored can be produced. More preferably, the binder is starch derived from corn starch, more preferably a modified starch derived from corn starch, and among them, the substituent by chemical reaction. It is possible to use corn starch that is partially or completely alpha-enriched, obtained by dispersing corn starch, which is preferable to corn starch, and then heating it. Particularly preferred.
- the present invention provides a tablet containing droxidopa as an active ingredient.
- the tablet is characterized in that it contains at least one excipient selected from mannitol, lactose, erythritol, glucose, sucrose, crystalline cellulose and corn-derived starch, and is further derived from corn as a binder. It may contain starch and / or polyvinyl alcohol.
- the tablet of the present invention can be produced through a granulation step or by a direct tableting method.
- the tablet of the present invention is preferably a high-dose droxidopa tablet containing 20-80% of the active ingredient droxidopa based on the total weight of the tablet.
- droxidopa is contained in an amount of 20% by weight or more, preferably 40% by weight or more, more preferably 50% by weight or more of the total weight of the tablet.
- the binder is preferably corn-derived starch.
- corn starch that has not been chemically modified, such as introduction of a substituent by chemical reaction, is more preferable.
- starch Particular preference is given to using starch.
- the tablet of the present invention is preferably at least one excipient selected from mannitol, lactose, erythritol, dalcose, sucrose, crystalline cellulose and corn-derived starch, and part or all as a binder.
- the tablet of the present invention preferably contains 15% to 78% of the excipient based on the total weight of the tablet and usually contains 1% to 6% of the binder.
- the binder is a modified starch derived from corn starch and corn starch, it preferably contains 0.3% to 6%, more preferably 0.5 to 5%, and the binder is polybulal alcohol. In the case, it preferably contains 0.001% to 5%, more preferably 0.001 to 4%.
- the tablet of the present invention does not substantially contain a binder other than corn-derived starch or polybulal alcohol. This is because the binder other than corn-derived starch or polyvinyl alcohol contains droxidopa. This is because it affects sex.
- the tablet of the present invention is substantially free of binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose, hydroxypropylcellulose, agar, gelatin and the like.
- binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose, hydroxypropylcellulose, agar, gelatin and the like.
- these binders may be contained in an amount that does not adversely affect the stability (colorability) of the tablet.
- the tablet of the present invention includes an intraoral rapidly disintegrating tablet. That is, by using corn starch as a disintegrant, an intraoral quick disintegrating tablet containing droxidopa that can withstand long-term storage without coloring as an active ingredient can be produced.
- the tablet containing droxidopa of the present invention as an active ingredient is an orally rapidly disintegrating tablet, the following (1) and (2):
- At least one excipient selected from mannitol, erythritol and lactose,
- the intraoral quick disintegrating tablet of the present invention may contain corn-derived starch and Z or polybulu alcohol as a binder.
- mannitol can be preferably used as an excipient.
- the binder preferably includes corn-derived starch. More preferably, it is a modified starch derived from corn, and is obtained by dispersing corn starch preferred by corn starch in water, followed by heating after chemical modification such as introduction of a substituent by chemical reaction. It is particularly preferable to use corn starch partially or entirely alpha-ized.
- the intraoral quick disintegrating tablet of the present invention is particularly preferably a tablet containing mann starch and corn starch partially or wholly alpha-ized.
- the content ratio of the listed excipient and the total amount of starch derived from corn is preferably 5: 5 to 9.5: 0.5, more preferably 6: 4 to 9: 1.
- the “total amount of corn-derived starch” refers to corn starch or partially pregelatinized starch as a disintegrant and corn-derived starch (including corn starch and corn-derived modified starch) as a binder. Represents the total amount.
- the binder is usually contained in an amount of 0.001% to 5% by weight. Specifically, if the binder is starch derived from corn, preferably 0.3 to 5 weight 0/0, is contained more preferably 0.5 to 3 wt%, when the binder is poly Bulle alcohol, preferably 0.001
- the intraoral quick disintegrating tablet of the present invention contains substantially no binder other than corn-derived starch or polybutyl alcohol, but the binder is generally used in the oral cavity. This is because it works to prevent rapid disintegration of the tablet, and binding agents other than corn-derived starch or polybulu alcohol affect the stability of tablets containing droxidopa.
- the tablet of the present invention does not substantially contain a binder such as polyvinylpyrrolidone, hydroxypropylmethylcellulose, hydroxypropylcellulose, agar, gelatin and the like.
- these binders may be contained in an amount that does not adversely affect the disintegration and stability (colorability) of the tablet.
- a disintegrating agent for the purpose of disintegration, molding, stabilization, taste improvement, etc.
- Supplementary ingredients that are acceptable for use as pharmaceuticals, such as acidulants, fragrances, pigments, preservatives, antioxidants, stabilizers, and surfactants, can be used as appropriate.
- a lubricant is used in the production of a tablet in the present invention.
- examples of lubricants that can be used as long as they are acceptable for use as pharmaceuticals are not limited in both type and amount.
- magnesium stearate, stearic acid, calcium stearate, sodium stearyl fumarate, sucrose fatty acid ester examples include talc, hydrogenated oil, and carvarna wax. It is desirable to set an appropriate amount within a range that does not affect the disintegration of the tablet. It is effective to perform tableting with a small amount of lubricant by the external lubricant method.
- the internal lubrication method about 0.5 to 3% by weight of lubricant is usually added. Less by external lubrication method! /, In quantity In order to show a lubrication effect, about 0.05 to 0.5% by weight is usually added.
- the tablet production method in the present invention is not particularly limited, and can be produced by a method widely used by those skilled in the art.
- Droxidopa (2) Mannitol, lactose, erythritol, glucose, sucrose, crystalline cellulose and corn-derived starch. Power selected excipient, and optionally corn-derived starch as binder And an additive such as Z or polybulal alcohol.
- corn starch or corn-derived partially alpha-integrated starch is added as a disintegrant.
- a lubricant can be added and mixed, and compression-molded with an appropriate tableting machine such as a rotary tableting machine, a single-shot tableting machine, or a hydraulic press machine to obtain a tablet. It is also possible to tablet by an external lubricant method without adding a lubricant to the mixture.
- the water content in the tablet is preferably 1% by weight or less, more preferably 0.8% by weight or less, still more preferably 0.6% by weight or less, and particularly preferably 0.4% by weight or less.
- the additive represents components other than droxidopa, such as an excipient, a disintegrant, a binder, and a lubricant, contained in the tablet of the present invention.
- each of the above production steps is preferably performed under dry conditions as much as possible.
- the moisture immediately after granulation is preferably 1.5% by weight or less, more preferably 1% by weight, and even more preferably 0.6% by weight. %, Particularly preferably 0.4% by weight or less.
- the intermediate is immediately dried by heating or blowing.
- Examples of the granulation method include an extrusion granulation method, a compression granulation method, a melt granulation method, a spray drying granulation method, a fluidized bed granulation method, a crushing granulation method, and a stirring granulation method.
- the tablet of the present invention is preferably provided by enclosing a hygroscopic agent such as silica gel, if necessary.
- a pulverized product For droxidopa, it is preferable to use a pulverized product.
- a force not particularly limited as the average particle diameter is preferably 20 to 500 m, more preferably 20 to 200 m, and further preferably 20 to LOO / z m.
- the average particle size of droxidopa as a raw material is particularly preferably 25 to 50 m.
- the particle size distribution of droxidopa is as uniform as possible. Specifically, 90% D is 200 / z m or less, preferably 160 m or less.
- the pulverization method include those using an airflow pulverizer or a Nommer pulverizer.
- the tablet of the present invention has a hardness of 30N or more.
- 9-llmm tablets can be produced for 200 mg droxidopa-containing preparations, and about 7-9 mm tablets can be produced for lOOmg droxidopa-containing preparations.
- the shape of the tablet in the present invention is not particularly limited, and may be any of a round tablet, a round R tablet, a round corner tablet, an oval tablet, various atypical tablets, and the like. Moreover, it is good also as a split tablet.
- Corn starch Product name Cornstarch (XX16) W (manufactured by Nippon Shokuhin Kako)
- Xylitol Product name Xylit fine powder (manufactured by Towa Kasei Kogyo)
- Methylcellulose Product name Metroles SM-25 (manufactured by Shin-Etsu Chemical)
- Corn starch Product name Solar eclipse corn starch W (manufactured by Nippon Shokuhin Kako)
- Microcrystalline cellulose Product name Avicel PH-102 (Asahi Kasei)
- Rice starch Product name Micropearl (manufactured by Shimada Chemical Industries)
- the stability of the tablet of Example 1 was evaluated.
- Table 2 shows the appearance changes.
- the appearance criteria are as follows:
- the tablets of Formulation 1 were stable after storage for 3 months at 25 ° C and 1-6 months at 40 ° C. Furthermore, it is possible to reduce the moisture content in the tablet by encapsulating silica gel in a storage bottle, but by storing Formulation 1 in the presence of a desiccant (silica gel), the more severe 60 ° C1 It was found that coloring was suppressed even after storage for months and the stability was further improved. That is, the tablet of the present invention is more preferably filled with a desiccant such as silica gel! /.
- Example 3 From the above results, the tablet of Example 1 was stable with little change in appearance. As a result, there was almost no change in the droxidopa content in the tablets at 25 ° C for 3 months and at 40 ° C for 3 months, indicating that this preparation is chemically stable.
- Magnesium stearate 3 Trace amount The tablet prepared by the above formulation was sealed in a brown glass bottle and stored in a sealed container at 40 ° C. The results are shown in Table 5.
- the preparation containing xylitol and methylcellulose of Comparative Example 1 had a black spot on the tablet after 1 month, and the stability was very bad.
- a mixture of droxidopa and the following excipients in a mortar 1: 1 is compressed with a hydraulic press (manufactured by Riken) at a pressure of 20 kgf / cm 2 , and the resulting tablets are either 60 ° C (warm) or It was stored at 40 ° C / 75% RH (humidified) for 2 weeks.
- the ingredients of Formulation 4 or 5 shown in Table 10 were mixed, and then magnesium stearate suspended in ethanol was applied and dried.
- the pestle and mortar were used to compress a tablet with a hydraulic table press (manufactured by NPa System) at a pressure of 1200 kgf to obtain a tablet having a diameter of 10 mm and a weight of 400 mg.
- the particle size of the drug substance and the 90% D value are the laser diffraction particle size distribution analyzer (Shimadzu SALD-300 0J), measured by a dry method.
- a mixture other than magnesium stearate can be added using a spray duller-ureter (RABO-1, manufactured by Paurek) or a flow coater (FLO-5, manufactured by Freund Corporation).
- the mixture was granulated by spraying 1% starch paste as a binding solution in an amount of 2.4 mg per tablet.
- the binding liquid was prepared by dispersing corn starch in water to prepare a 1% dispersion, and heating until just before boiling. The state in the fluidized bed during granulation was observed, and the manufacturability (manufacturing strength) was evaluated.
- the angle of repose of the granulated granule was measured (Angle of repose measuring instrument (manufactured by Konishi Seisakusho)).
- n. d . No data Regarding texture and ease of use, the smaller the particle size, the better. In addition, those seasoned with a small amount of organic acid and sweetener showed better values when compared to those not seasoned using the same drug substance. On the other hand, about the handling (manufacturability) at the time of manufacture
- Table 14 also shows the results of stability tests for formulations 4 and 5.
- the prepared preparations 4 and 5 were sealed in a brown glass bottle in the presence of silica gel and stored at 60 ° C, and changes in appearance and related substances were measured. As a result, we were able to see 0.1% or more related substances with little change in appearance.
- Formulations 6 and 7 having the formulation shown in Table 15 below were produced.
- the powder raw material was mixed, and tableted by the same method and conditions as in Example 6 to obtain tablets.
- the raw materials were mixed in a mortar, kneaded with a 5% strength PVA binder, dried at 80 ° C for 1 hour, and then sieved with a # 30 sieve to obtain granules. Tablets were obtained by tableting in the same manner as in Preparation 6.
- Table 16 shows the results of the stability tests of Formulations 6 and 7.
- the prepared preparations 6 and 7 were sealed in a brown glass bottle in the presence of silica gel and stored at 60 ° C., and changes in appearance and related substances were measured. As a result, the change in color difference with a small change in appearance was small, which proved to be a preparation.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/914,693 US8980316B2 (en) | 2005-05-18 | 2006-05-17 | Stable tablet containing droxidopa |
CA2608690A CA2608690C (en) | 2005-05-18 | 2006-05-17 | Stable tablet containing droxidopa |
CN2006800172020A CN101180046B (zh) | 2005-05-18 | 2006-05-17 | 含有屈昔多巴的稳定片剂 |
ES06746504.7T ES2633088T3 (es) | 2005-05-18 | 2006-05-17 | Comprimido estable que contiene droxidopa |
JP2007516308A JP5219508B2 (ja) | 2005-05-18 | 2006-05-17 | ドロキシドパを含有する安定な錠剤 |
DK06746504.7T DK1886678T3 (en) | 2005-05-18 | 2006-05-17 | STABLE TABLET CONTAINING DROXIDOPA |
KR1020077026339A KR101435199B1 (ko) | 2005-05-18 | 2006-05-17 | 드록시도파를 함유하는 안정한 정제 |
EP06746504.7A EP1886678B1 (en) | 2005-05-18 | 2006-05-17 | Stable tablet containing droxidopa |
HK08112403.8A HK1120726A1 (en) | 2005-05-18 | 2008-11-12 | Stable tablet containing droxidopa |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-145831 | 2005-05-18 | ||
JP2005145831 | 2005-05-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006123678A1 true WO2006123678A1 (ja) | 2006-11-23 |
Family
ID=37431251
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/309801 WO2006123678A1 (ja) | 2005-05-18 | 2006-05-17 | ドロキシドパを含有する安定な錠剤 |
Country Status (10)
Country | Link |
---|---|
US (1) | US8980316B2 (ja) |
EP (1) | EP1886678B1 (ja) |
JP (2) | JP5219508B2 (ja) |
KR (1) | KR101435199B1 (ja) |
CN (1) | CN101180046B (ja) |
CA (1) | CA2608690C (ja) |
DK (1) | DK1886678T3 (ja) |
ES (1) | ES2633088T3 (ja) |
HK (1) | HK1120726A1 (ja) |
WO (1) | WO2006123678A1 (ja) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008127320A (ja) * | 2006-11-20 | 2008-06-05 | Zensei Yakuhin Kogyo Kk | 口腔内速崩壊性固形製剤 |
EP2062599A1 (en) * | 2006-09-14 | 2009-05-27 | Astellas Pharma Inc. | Orally disintegrating tablet and process for production thereof |
JP2009185083A (ja) * | 2005-05-18 | 2009-08-20 | Dainippon Sumitomo Pharma Co Ltd | ドロキシドパを含有する安定な錠剤 |
WO2009151072A1 (ja) * | 2008-06-13 | 2009-12-17 | 大日本住友製薬株式会社 | 口腔内速崩壊錠及びその製造方法 |
JP2012051810A (ja) * | 2010-08-31 | 2012-03-15 | Zensei Yakuhin Kogyo Kk | 口腔内崩壊錠およびその製造法 |
WO2012091049A1 (ja) * | 2010-12-28 | 2012-07-05 | 大鵬薬品工業株式会社 | 口腔内崩壊錠剤 |
CN103086906A (zh) * | 2011-11-03 | 2013-05-08 | 重庆圣华曦药业股份有限公司 | 屈昔多巴的晶型及其制备方法 |
WO2013116325A1 (en) * | 2012-01-31 | 2013-08-08 | Chelsea Therapeutics, Inc. | Improving postural stability administering droxidopa |
WO2014148520A1 (ja) * | 2013-03-21 | 2014-09-25 | 大正製薬株式会社 | 固形製剤 |
US9364453B2 (en) | 2011-05-17 | 2016-06-14 | Lundbeck Na Ltd. | Method of treating postural reflex abnormality caused by parkinson's disease |
JP2019511512A (ja) * | 2016-03-30 | 2019-04-25 | ピラマル エンタープライジーズ リミテッド | ドロキシドパを製造するための改良された方法及びその中間体 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2395868T3 (es) * | 2007-03-12 | 2013-02-15 | Chelsea Therapeutics, Inc. | Droxidopa y composición farmacéutica de la misma para el tratamiento de la hipotensión mediada neuralmente |
EP2514417A3 (en) * | 2007-05-07 | 2013-01-30 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders |
KR101381060B1 (ko) | 2009-05-19 | 2014-04-11 | 셀진 코포레이션 | 4-아미노-2-(2,6-디옥소피페리딘-3-일)이소인돌린-1,3-디온의 제제 |
JP6245786B2 (ja) * | 2011-10-17 | 2017-12-13 | 大同化成工業株式会社 | 医薬用結合剤及び該結合剤を用いた製剤 |
US20150210667A1 (en) * | 2012-05-10 | 2015-07-30 | Mahesh Kandula | Compositions and methods for the treatment of autonomic and other neurological disorders |
KR20160100663A (ko) | 2015-02-16 | 2016-08-24 | 엄태성 | 활성탄 숯 타일제조방법 |
JP2017001989A (ja) * | 2015-06-11 | 2017-01-05 | ニプロ株式会社 | 医薬組成物の製造方法及び医薬組成物 |
JP7020688B2 (ja) * | 2016-06-28 | 2022-02-16 | 株式会社日本抗菌総合研究所 | 賦形剤及び錠剤 |
WO2024023261A1 (en) * | 2022-07-27 | 2024-02-01 | Universität Zürich | Dexmedetomidine for the treatment of sleep disorders |
WO2024108082A1 (en) | 2022-11-18 | 2024-05-23 | Aprecia Pharmaceuticals LLC | Orodispersive dosage forms containing droxidopa |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5049252A (ja) * | 1973-08-22 | 1975-05-01 | ||
JPS52125630A (en) * | 1976-04-14 | 1977-10-21 | Kyowa Hakko Kogyo Co Ltd | Antiperkinson drugs containing l-threo-3,4-dihydroxyphenylserine |
WO2000047233A1 (fr) | 1999-02-15 | 2000-08-17 | Sumitomo Pharmaceuticals Co., Ltd. | Comprimes se desintegrant rapidement dans la cavite buccale |
WO2001064190A1 (fr) | 2000-03-01 | 2001-09-07 | Eisai Co., Ltd. | Comprimes se desagregeant rapidement contenant du poly(alcool de vinyle) |
WO2004100929A1 (en) * | 2003-05-12 | 2004-11-25 | Synergia Pharma, Inc. | Threo-dops controlled release formulation |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3920728A (en) * | 1973-08-22 | 1975-11-18 | Hoffmann La Roche | Separation and resolution of isomeric forms of 3-(3,4-dihydroxy-phenyl)-serine |
JP3701990B2 (ja) * | 1994-08-19 | 2005-10-05 | ピジョン株式会社 | ゴオウを成分とする小児五疳薬剤 |
AU713462B2 (en) * | 1996-07-12 | 1999-12-02 | Daiichi Pharmaceutical Co., Ltd. | Quickly disintegrable compression-molded materials and process for producing the same |
JPH115738A (ja) * | 1997-06-15 | 1999-01-12 | Katsuhiro Nishino | 脳虚血に伴う神経脱落症状の予防剤および超急性期治療剤 |
US6465009B1 (en) * | 1998-03-18 | 2002-10-15 | Yamanouchi Pharmaceutical Co., Ltd. | Water soluble polymer-based rapidly dissolving tablets and production processes thereof |
AU3344399A (en) * | 1998-04-16 | 1999-11-08 | City of Osaka, The | Remedies for primary biliary cirrhosis |
US20020177593A1 (en) * | 1998-09-30 | 2002-11-28 | Yuji Ishihara | Agents and crystals for improving excretory potency of urinary bladder |
US20030026835A1 (en) * | 1999-02-15 | 2003-02-06 | Sumitomo Pharmaceuticals Company Limited | Tablets disintegrating rapidly in the oral cavity |
JP4802436B2 (ja) | 2000-04-12 | 2011-10-26 | Msd株式会社 | 口腔内崩壊型組成物及び口腔内崩壊型製剤 |
DE60138722D1 (de) * | 2000-09-22 | 2009-06-25 | Dainippon Sumitomo Pharma Co | Orale zubereitungen mit vorteilhaften zerfallseigenschaften |
JP2002363067A (ja) | 2001-06-06 | 2002-12-18 | Shin Etsu Chem Co Ltd | 錠剤の製造方法 |
JP2003095928A (ja) | 2001-09-27 | 2003-04-03 | Kowa Co | 糖衣製剤 |
FR2841138B1 (fr) * | 2002-06-25 | 2005-02-25 | Cll Pharma | Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation |
DK1523984T3 (da) * | 2003-10-13 | 2007-03-26 | Zoser B Salama | Farmaceutisk sammensætning indeholdende oxoplatin og dettes salte |
WO2006123678A1 (ja) | 2005-05-18 | 2006-11-23 | Dainippon Sumitomo Pharma Co., Ltd. | ドロキシドパを含有する安定な錠剤 |
BRPI0609984A2 (pt) | 2005-05-25 | 2010-05-18 | Transcept Pharmaceuticals Inc | uso de zolpidem ou um sal do mesmo |
PT1884242E (pt) | 2005-05-26 | 2013-05-21 | Dainippon Sumitomo Pharma Co | Composição farmacêutica compreendendo lurasidona |
WO2008018371A1 (fr) | 2006-08-08 | 2008-02-14 | Kissei Pharmaceutical Co., Ltd. | Comprimé à désagrégation orale ayant un goût amer masqué et son procédé de production |
US9119820B2 (en) * | 2008-06-13 | 2015-09-01 | Sumitomo Dainippon Pharma Co., Ltd. | Tablet quickly disintegrating in the oral cavity and method for producing the same |
-
2006
- 2006-05-17 WO PCT/JP2006/309801 patent/WO2006123678A1/ja active Application Filing
- 2006-05-17 JP JP2007516308A patent/JP5219508B2/ja active Active
- 2006-05-17 US US11/914,693 patent/US8980316B2/en active Active
- 2006-05-17 KR KR1020077026339A patent/KR101435199B1/ko active IP Right Grant
- 2006-05-17 DK DK06746504.7T patent/DK1886678T3/en active
- 2006-05-17 EP EP06746504.7A patent/EP1886678B1/en active Active
- 2006-05-17 ES ES06746504.7T patent/ES2633088T3/es active Active
- 2006-05-17 CA CA2608690A patent/CA2608690C/en active Active
- 2006-05-17 CN CN2006800172020A patent/CN101180046B/zh active Active
-
2008
- 2008-11-12 HK HK08112403.8A patent/HK1120726A1/xx unknown
-
2009
- 2009-05-29 JP JP2009130801A patent/JP5219924B2/ja active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5049252A (ja) * | 1973-08-22 | 1975-05-01 | ||
JPS52125630A (en) * | 1976-04-14 | 1977-10-21 | Kyowa Hakko Kogyo Co Ltd | Antiperkinson drugs containing l-threo-3,4-dihydroxyphenylserine |
WO2000047233A1 (fr) | 1999-02-15 | 2000-08-17 | Sumitomo Pharmaceuticals Co., Ltd. | Comprimes se desintegrant rapidement dans la cavite buccale |
WO2001064190A1 (fr) | 2000-03-01 | 2001-09-07 | Eisai Co., Ltd. | Comprimes se desagregeant rapidement contenant du poly(alcool de vinyle) |
WO2004100929A1 (en) * | 2003-05-12 | 2004-11-25 | Synergia Pharma, Inc. | Threo-dops controlled release formulation |
Non-Patent Citations (2)
Title |
---|
BYOIN YAKUGAKU, vol. 11, no. 3, 1985, pages 284 - 292 |
See also references of EP1886678A4 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009185083A (ja) * | 2005-05-18 | 2009-08-20 | Dainippon Sumitomo Pharma Co Ltd | ドロキシドパを含有する安定な錠剤 |
US8980316B2 (en) | 2005-05-18 | 2015-03-17 | Sumitomo Dainippon Pharma Co., Ltd. | Stable tablet containing droxidopa |
EP2062599A4 (en) * | 2006-09-14 | 2013-03-27 | Astellas Pharma Inc | ORAL DISSOLVING TABLET AND METHOD FOR THE PRODUCTION THEREOF |
EP2062599A1 (en) * | 2006-09-14 | 2009-05-27 | Astellas Pharma Inc. | Orally disintegrating tablet and process for production thereof |
JP2008127320A (ja) * | 2006-11-20 | 2008-06-05 | Zensei Yakuhin Kogyo Kk | 口腔内速崩壊性固形製剤 |
US9119820B2 (en) | 2008-06-13 | 2015-09-01 | Sumitomo Dainippon Pharma Co., Ltd. | Tablet quickly disintegrating in the oral cavity and method for producing the same |
JP5583012B2 (ja) * | 2008-06-13 | 2014-09-03 | 大日本住友製薬株式会社 | 口腔内速崩壊錠及びその製造方法 |
KR101618388B1 (ko) | 2008-06-13 | 2016-05-04 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 구강 내 급속 붕해 정제 및 이의 제조 방법 |
WO2009151072A1 (ja) * | 2008-06-13 | 2009-12-17 | 大日本住友製薬株式会社 | 口腔内速崩壊錠及びその製造方法 |
AU2009258560B2 (en) * | 2008-06-13 | 2014-07-10 | Sumitomo Pharma Co., Ltd. | Tablet quickly disintegrating in the oral cavity and method for producing the same |
JP2012051810A (ja) * | 2010-08-31 | 2012-03-15 | Zensei Yakuhin Kogyo Kk | 口腔内崩壊錠およびその製造法 |
JPWO2012091049A1 (ja) * | 2010-12-28 | 2014-06-05 | 大鵬薬品工業株式会社 | 口腔内崩壊錠剤 |
WO2012091049A1 (ja) * | 2010-12-28 | 2012-07-05 | 大鵬薬品工業株式会社 | 口腔内崩壊錠剤 |
JP5876418B2 (ja) * | 2010-12-28 | 2016-03-02 | 大鵬薬品工業株式会社 | 口腔内崩壊錠剤 |
US9364453B2 (en) | 2011-05-17 | 2016-06-14 | Lundbeck Na Ltd. | Method of treating postural reflex abnormality caused by parkinson's disease |
CN103086906B (zh) * | 2011-11-03 | 2015-04-01 | 重庆圣华曦药业股份有限公司 | 屈昔多巴的晶型及其制备方法 |
CN103086906A (zh) * | 2011-11-03 | 2013-05-08 | 重庆圣华曦药业股份有限公司 | 屈昔多巴的晶型及其制备方法 |
WO2013116325A1 (en) * | 2012-01-31 | 2013-08-08 | Chelsea Therapeutics, Inc. | Improving postural stability administering droxidopa |
WO2014148520A1 (ja) * | 2013-03-21 | 2014-09-25 | 大正製薬株式会社 | 固形製剤 |
JPWO2014148520A1 (ja) * | 2013-03-21 | 2017-02-16 | 大正製薬株式会社 | 固形製剤 |
JP2019511512A (ja) * | 2016-03-30 | 2019-04-25 | ピラマル エンタープライジーズ リミテッド | ドロキシドパを製造するための改良された方法及びその中間体 |
Also Published As
Publication number | Publication date |
---|---|
KR20080013907A (ko) | 2008-02-13 |
CA2608690A1 (en) | 2006-11-23 |
KR101435199B1 (ko) | 2014-08-28 |
EP1886678A1 (en) | 2008-02-13 |
CN101180046B (zh) | 2011-12-28 |
JP5219508B2 (ja) | 2013-06-26 |
EP1886678B1 (en) | 2017-04-19 |
CA2608690C (en) | 2016-07-05 |
EP1886678A4 (en) | 2009-06-10 |
US20090074861A1 (en) | 2009-03-19 |
JP5219924B2 (ja) | 2013-06-26 |
ES2633088T3 (es) | 2017-09-19 |
CN101180046A (zh) | 2008-05-14 |
JP2009185083A (ja) | 2009-08-20 |
US8980316B2 (en) | 2015-03-17 |
DK1886678T3 (en) | 2017-07-10 |
HK1120726A1 (en) | 2009-04-09 |
JPWO2006123678A1 (ja) | 2008-12-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5219924B2 (ja) | ドロキシドパを含有する安定な錠剤 | |
JP6092936B2 (ja) | 口腔内崩壊錠の製造方法 | |
ES2393640T3 (es) | Comprimidos bucodisgregables | |
KR101465803B1 (ko) | 구강내 붕괴 정제 | |
JP4706785B2 (ja) | 経口投与用粒子状医薬組成物 | |
JP4920798B2 (ja) | 2種以上の粒子を含有する口腔内速崩壊錠 | |
JP7336388B2 (ja) | 錠剤及びその製造方法 | |
JP2012051810A (ja) | 口腔内崩壊錠およびその製造法 | |
JP5275815B2 (ja) | リスペリドンを含有する口腔内崩壊錠剤および苦味抑制製剤 | |
JP4999297B2 (ja) | 高含量塩酸テルビナフィン小型錠剤 | |
JP2010001242A (ja) | レバミピド固形製剤及びその製造方法 | |
JP2011037767A (ja) | 薬物および噴霧乾燥粒子を含有する口腔内速崩壊錠 | |
TW201431553A (zh) | N-[5-[2-(3,5-二甲氧基苯基)乙基]-2h-吡唑-3-基]-4-[(3r,5s)-3,5-二甲基哌□-1-基]苯甲醯胺之醫藥調配物 | |
KR20180098282A (ko) | 압축 성형 제제 | |
JP2008189634A (ja) | 口腔内速崩錠の製造方法 | |
JP5502358B2 (ja) | 口腔内速崩壊性錠剤およびその製造方法 | |
TW202342054A (zh) | 經口固形製劑 | |
JP2011213606A (ja) | ドネペジルを含有する固形製剤の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680017202.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007516308 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077026339 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2608690 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11914693 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2006746504 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006746504 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006746504 Country of ref document: EP |